NCT04343794

Brief Summary

The novel coronavirus (COVID-19) emerged in December 2019, and in mere months has spread to more than 104 countries, resulting in an outbreak of viral pneumonia worldwide. Current local quarantine policy in Hong Kong for individuals suspected for COVID-19 requires daily self-reported symptomatology and body temperature, given the intermittent nature and the high dependency of self-discipline undermine the practicality of the approach. To date, the advance in sensor technology has made possible to continuously monitor individual physiological parameters using a simple wearable device. Together with the mobile wearable technology that allowing instantaneous, multi-directional, and massive data transfer, remote continuous physiological monitoring is made possible. The Cardiology division, the Univeristy of Hong Kong has been in collaboration with Biofourmis to implement such technology for remote heart failure management. Similar digital therapeutic system can be applied to remotely monitor physiological parameters of large number of quarantined or suspected COVID-19 at home or in quarantine facility. It is purposed to allow the monitoring team to effectively and remotely monitor COVID-19 quarantined and patients, manage and evaluate the disease progression.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P50-P75 for not_applicable covid19

Timeline
Completed

Started Apr 2020

Longer than P75 for not_applicable covid19

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 20, 2020

Completed
1 month until next milestone

Study Start

First participant enrolled

April 1, 2020

Completed
12 days until next milestone

First Posted

Study publicly available on registry

April 13, 2020

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2022

Completed
Last Updated

April 15, 2020

Status Verified

April 1, 2020

Enrollment Period

1.8 years

First QC Date

February 20, 2020

Last Update Submit

April 13, 2020

Conditions

Keywords

Wearable physiological monitor

Outcome Measures

Primary Outcomes (1)

  • Time to diagnosis of COVID-19 by RT-PCR in subjects

    Time from quarantine to diagnosis of COVID-19

    within 14 days

Secondary Outcomes (9)

  • Compliance to complete the study

    within 14 days

  • Sensitivity and specificity of Biovitals® Sentinel

    within 14 days

  • Cross infection rate within the family cluster

    within 14 days

  • Length of hospital stay of positive subjects

    1 year at study completion

  • Length of ICU stay of positive patients

    1 year at study completion

  • +4 more secondary outcomes

Study Arms (2)

Biovitals

EXPERIMENTAL

Continuous physiological monitoring using Biovitals platform including (1) armband with multiple physiological sensor, (2) remote monitoring, and (3) Analytic platform. The arm will be worn 23 hours a day and off for 1 hour during showering for recharging battery during 24 hr quarantine period

Device: BIOVITALS

Control

NO INTERVENTION

Usual standard care

Interventions

BIOVITALSDEVICE

Biovitals platform including (1) armband with multiple physiological sensor, (2) remote monitoring, and (3) Analytic platform. The arm will be worn 23 hours a day and off for 1 hour during showering for recharging battery during 24 hr quarantine period

Biovitals

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult subjects ≥18 years of age
  • Quarantined as suspected COVID-19
  • Asymptomatic upon enrolment
  • All subjects give written informed consent

You may not qualify if:

  • \- Failure to provide written informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The University of Hong Kong, Queen Mary Hospital

Hong Kong, Hong Kong

RECRUITING

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Officials

  • David Siu, MD FRCP

    HKU

    PRINCIPAL INVESTIGATOR

Central Study Contacts

David Siu, MD FRCP

CONTACT

Ivan Hung, MD FRCPath

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

February 20, 2020

First Posted

April 13, 2020

Study Start

April 1, 2020

Primary Completion

December 31, 2021

Study Completion

January 31, 2022

Last Updated

April 15, 2020

Record last verified: 2020-04

Locations